Novavax RSV Vaccine Clinical Trial shows efficacy in older adults
by Staff from Outbreak News Today on (#H5DC)
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older). The RSV F Vaccine was ["]
